Follow

Submissions from 2016

PDF

Treatment of a chemoresistant neuroblastoma cell line with the antimalarial ozonide OZ513., Don W. Coulter, Timothy R. McGuire, J. Graham Sharp, Erin M. McIntyre, Yuxiang Dong, Xiaofang Wang, Shawn Gray, Gracey R. Alexander, Nagendra K. Chatuverdi, Shantaram Joshi, Xiaoyu Chen, and Jonathan L. Vennerstrom

PDF

Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism., Maureen A. Smythe, Jennifer Priziola, Paul P. Dobesh, Diane Wirth, Adam Cuker, and Ann K. Wittkowsky

Submissions from 2015

PDF

Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities., Paul P. Dobesh and John Fanikos

PDF

Impact of a high-fat meal on assessment of clopidogrel-induced platelet inhibition in healthy subjects., Paul P. Dobesh, Jamela F. Urban, Scott W. Shurmur, and Julie H. Oestreich

Submissions from 2014

PDF

New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities., Paul P. Dobesh and John Fanikos

PDF

Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety., Paul P. Dobesh and Julie H. Oestreich

PDF

Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications., Toby Trujillo and Paul P. Dobesh